Poly-arginine Peptides Modulate PSD-95 Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neural stress conditions such as depression, autism, and neurodegenerative diseases like Alzheimer's and ALS lack effective agents that can modulate PSD-95 signaling to prevent brain damage from excitotoxicity and inflammation.
Innovation Solution
Development of compounds with a specific structure that act as reversible agonists of the PDZ3 domain of PSD-95, comprising amino acids, peptide chains, and molecular transporters, which bind to the PDZ3 domain to modulate signaling and reduce neuroinflammation and excitotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for neural stress conditions, then existing therapeutic approaches are available, but they lack effective agents to modulate PSD-95 signaling and prevent brain damage
Solution Approach 1:
The patent modifies the peptide structure by changing parameters such as amino acid composition, peptide length, and molecular weight to create compounds that specifically bind to PDZ3 domain with high affinity, enabling effective modulation of PSD-95 signaling that current treatments cannot achieve
Solution Approach 2:
The invention creates composite peptide structures combining specific amino acid sequences with molecular transporters (such as cell-penetrating peptides or liposome conjugates), forming hybrid molecules that can both bind PDZ3 domain and deliver therapeutic effects across biological barriers
2Reliability
If high affinity binding to PDZ3 domain is achieved, then BDNF signaling is enhanced, but the structural complexity of the compound increases
Solution Approach 1:
The compound is divided into functional segments: a PDZ3-binding peptide domain (specific amino acid sequence) and a molecular transporter domain, allowing each segment to perform its specific function while maintaining overall effectiveness
Solution Approach 2:
The molecular transporter component serves multiple functions including cellular uptake, blood-brain barrier penetration, and targeted delivery, reducing the need for separate delivery systems and simplifying the overall therapeutic approach
3Object-affected harmful factors
If reversible agonists are developed to modulate signaling, then neuroinflammation and excitotoxicity are reduced, but the difficulty of detecting and measuring the compounds increases
Solution Approach 1:
The patent uses reporter gene systems and fluorescently labeled peptides as intermediaries to detect compound activity, translating complex molecular interactions into measurable signals that indicate modulation of PSD-95 signaling and reduction of neuroinflammation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively bind to the PDZ3 domain with high affinity, enhancing BDNF signaling, restoring synaptic strength, and reducing inflammatory cytokines, thereby providing therapeutic benefits for neural stress conditions.
Implementation Method 1
These compounds effectively bind to the PDZ3 domain with high affinity
Data Source
AI summary
Provided herein are compounds and compositions that are reversible agonists of the PDZ3 domain of PSD-95. Methods of their use in treating conditions of neural stress, inflammation, and viability are also provided.